You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 4, April 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Gastrointestinal Diseases
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Colorectal Surgery
 •Colon Cancer
 •Oncology, Other
 •Drug Therapy
 •Alert me on articles by topic

First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases

Gennaro Galizia, MD; Eva Lieto, MD; Michele Orditura, MD; Paolo Castellano, MD; Vincenzo Imperatore, MD; Margherita Pinto, MD; Anna Zamboli, MD

Arch Surg. 2008;143(4):352-358.

Hypothesis  Bowel resection followed by chemotherapy is a better management strategy than immediate chemotherapy in asymptomatic patients with colorectal cancer and unresectable liver-only metastases at presentation.

Design  Retrospective study.

Setting  University hospital.

Patients  Sixty-five consecutive symptom-free colorectal cancer patients with unresectable synchronous metastases confined to the liver undergoing bowel tumor resection plus systemic chemotherapy (42 patients [resection group]) or chemotherapy first (23 patients [chemotherapy group]).

Main Outcome Measures  Long-term survival and identification of prognostic indicators of outcome.

Results  In the resection group, the mean and median overall survival times were shown to be significantly better than those in the chemotherapy group (P = .03). Performance status, basal serum levels of lactic dehydrogenase and alkaline phosphatase, percentage of liver involvement, potentially curative resection of the bowel tumor, and type of treatment (resection vs chemotherapy) were demonstrated to be the only variables significantly correlated with long-term survival. On multivariate analysis, performance status, extent of liver involvement, and type of treatment were shown to be the only covariates independently associated with survival rate. The rate of liver metastasis downstaging with subsequent curative hepatic resection was clearly associated with good performance status, limited liver involvement, and resection of the bowel tumor.

Conclusions  Achieving complete cure in asymptomatic colorectal cancer patients with unresectable synchronous liver-only metastases appears to be mostly the result of shrinkage and resection of hepatic metastases. In patients with good performance status and limited liver involvement, bowel tumor resection appears to be the best treatment option for this purpose.


Author Affiliations: Divisions of Surgical Oncology (Drs Galizia, Lieto, Castellano, Imperatore, Pinto, and Zamboli) and Medical Oncology (Dr Orditura), "F. Magrassi–A. Lanzara" Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, Naples, Italy.


RELATED ARTICLE

First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases—Invited Critique
Gregory Kennedy and Heidi Nelson
Arch Surg. 2008;143(4):358.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.